Guidance for Vanda Pharma (VNDA)
| Period | Range | Estimate | Revenue Range | Revenue Estimate | Target | Details |
|---|---|---|---|---|---|---|
| 2026 | N/A | N/A | $240.00M – 290.00M | $258.20M | = Maintained | Details |
| 2026 | N/A | N/A | $230.00M – 260.00M | $271.30M | = Maintained | Details |
| 2025 | N/A | N/A | $210.00M – 230.00M | $224.80M | = Maintained | Details |
| 2025 | N/A | N/A | $210.00M – 250.00M | $227.70M | = Maintained | Details |
| 2025 | N/A | N/A | $210.00M – 250.00M | $222.90M | = Maintained | Details |
| 2025 | N/A | N/A | $210.00M – 250.00M | $284.90M | = Maintained | Details |
| 2024 | N/A | N/A | $190.00M – 210.00M | $197.40M | = Maintained | Details |
| 2024 | N/A | N/A | $180.00M – 210.00M | $220.20M | = Maintained | Details |
| 2022 | $240.00 – $280.00 | N/A | N/A | N/A | = Maintained | Details |
| 2022 | N/A | N/A | $240.00M – 280.00M | $313.62M |  Lowered |
Details |
| Q3 2022 | N/A | N/A | $240.00M – 280.00M | $265.10M | = Maintained | Details |
| 2020 | N/A | N/A | $240.00M – 260.00M | $251.05M | = Maintained | Details |
| 2020 | N/A | N/A | $240.00M – 260.00M | $247.77M | = Maintained | Details |
| 2020 | N/A | N/A | $240.00M – 260.00M | $274.60M | = Maintained | Details |
| 2019 | N/A | N/A | $215.00M – 225.00M | $224.80M | = Maintained | Details |
| 2019 | N/A | N/A | $215.00M – 225.00M | $219.56M | = Maintained | Details |
| 2019 | N/A | N/A | $215.00M – 225.00M | $221.36M | = Maintained | Details |
| Q3 2018 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q2 2018 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q1 2018 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q4 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q3 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q2 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q1 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
